Renaissance Technologies LLC trimmed its stake in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) by 14.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 178,600 shares of the company's stock after selling 31,000 shares during the period. Renaissance Technologies LLC owned about 0.14% of Centessa Pharmaceuticals worth $2,992,000 as of its most recent SEC filing.
Other hedge funds have also modified their holdings of the company. State Street Corp purchased a new stake in Centessa Pharmaceuticals in the 3rd quarter worth about $777,000. Geode Capital Management LLC lifted its stake in Centessa Pharmaceuticals by 68.7% in the 3rd quarter. Geode Capital Management LLC now owns 56,597 shares of the company's stock worth $905,000 after acquiring an additional 23,058 shares in the last quarter. Franklin Resources Inc. lifted its stake in Centessa Pharmaceuticals by 99.1% in the 3rd quarter. Franklin Resources Inc. now owns 2,302,546 shares of the company's stock worth $38,360,000 after acquiring an additional 1,145,823 shares in the last quarter. Lord Abbett & CO. LLC purchased a new stake in Centessa Pharmaceuticals in the 3rd quarter worth about $4,305,000. Finally, JPMorgan Chase & Co. lifted its stake in Centessa Pharmaceuticals by 1,969.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 135,903 shares of the company's stock worth $2,173,000 after acquiring an additional 129,335 shares in the last quarter. 82.01% of the stock is owned by hedge funds and other institutional investors.
Centessa Pharmaceuticals Stock Performance
Centessa Pharmaceuticals stock traded down $0.17 on Tuesday, hitting $13.59. The company's stock had a trading volume of 43,096 shares, compared to its average volume of 605,702. The firm has a market cap of $1.81 billion, a P/E ratio of -8.84 and a beta of 1.53. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15. The company has a fifty day moving average price of $14.38 and a 200-day moving average price of $15.86. Centessa Pharmaceuticals plc has a one year low of $7.75 and a one year high of $19.09.
Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last posted its earnings results on Monday, March 24th. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.38) by $0.04. On average, equities analysts anticipate that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current year.
Insider Transactions at Centessa Pharmaceuticals
In other Centessa Pharmaceuticals news, General Counsel Iqbal J. Hussain sold 6,000 shares of the stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $16.18, for a total transaction of $97,080.00. Following the sale, the general counsel now owns 105,386 shares of the company's stock, valued at $1,705,145.48. This represents a 5.39 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Gregory M. Weinhoff sold 11,742 shares of the company's stock in a transaction dated Friday, April 25th. The shares were sold at an average price of $13.61, for a total transaction of $159,808.62. Following the transaction, the insider now owns 122,279 shares in the company, valued at approximately $1,664,217.19. The trade was a 8.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 213,824 shares of company stock valued at $3,497,018. 11.59% of the stock is owned by insiders.
Wall Street Analyst Weigh In
Several research analysts have weighed in on the company. Piper Sandler assumed coverage on Centessa Pharmaceuticals in a research report on Monday, March 31st. They issued an "overweight" rating and a $38.00 target price on the stock. Guggenheim reissued a "buy" rating and set a $28.00 price objective on shares of Centessa Pharmaceuticals in a report on Wednesday, March 26th. Morgan Stanley reissued an "overweight" rating and set a $27.00 price objective on shares of Centessa Pharmaceuticals in a report on Friday, March 7th. Finally, TD Cowen assumed coverage on Centessa Pharmaceuticals in a report on Tuesday, January 7th. They issued a "buy" rating on the stock. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $27.71.
View Our Latest Report on Centessa Pharmaceuticals
Centessa Pharmaceuticals Company Profile
(
Free Report)
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.
See Also
Before you consider Centessa Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Centessa Pharmaceuticals wasn't on the list.
While Centessa Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
